NCT04716647View on ClinicalTrials.gov

Feasibility of Ayurveda in Patients With Mild-to-Moderate COVID-19: A Community-Based Participatory Research

NACompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

October 9, 2020

Primary Completion Date

December 12, 2020

Study Completion Date

December 18, 2020

Conditions
Covid19
Interventions
OTHER

Ayurveda

Dosage was used in common range (Ashwagandha: Doses range from 250 mg to 5 g; Giloy: range from 500mg to 1g; Tulsi: 500mg-1g) Dosage were altered based on age, weight and severity of symptoms.

Trial Locations (1)

Unknown

Aarogyam UK, Leicester

All Listed Sponsors
collaborator

University of Warwick

OTHER

collaborator

Dr. Sarvepalli Radhakrishnan Rajasthan Ayurved University

OTHER

lead

Aarogyam UK

OTHER

NCT04716647 - Feasibility of Ayurveda in Patients With Mild-to-Moderate COVID-19: A Community-Based Participatory Research | Biotech Hunter | Biotech Hunter